



Date: October 13, 2022

To,

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA
---	---

Dear Sir/Madam,

Subject: Certificate pursuant to Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2022

With reference to the subject captioned above, please find enclosed herewith the Quarterly Reconciliation of Share Capital Audit Report pursuant to Regulation 76 of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30, 2022.

Kindly take the same on record and acknowledge the receipt.

Thanking you,

For Supriya Lifescience Limited

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

Mahesh M. Darji

Practicing Company Secretary
B.Com., DBM, LLB, FCS

To,
The Board of Directors,
Supriya Lifescience Limited
MUMBAI

SUB: Reconciliation of Share Capital Audit Certificate in terms of Regulation 76 of SEBI (Depositories & Participants) Regulations, 2018


Dear Sirs,

I have examined the Register of Members, Beneficiary details furnished by the depositories and other records/ documents maintained by **Supriya Lifescience Limited** (hereinafter referred to as "the Company") and **Link Intime India Private Limited** the Registrar and Transfer Agent of the Company, for issuing of this certificate in accordance with Regulation 76 of SEBI (Depositories & Participants) Regulations, 2018.

In my opinion and to the best of my information and according to the explanations given to me and based on such verification as considered necessary, I hereby certify that:

1	For Quarter Ended	30.09.2022	
2	ISIN	INE07RO01027	
3	Face Value	Equity Shares of Rs. 2/- each	
4	Name of the Company	Supriya Lifescience Limited	
5	Registered Office Address	207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063	
6	Correspondence Address	As above	
7	Telephone & Fax Nos.	Tel. No. +91 22 40332727; Fax No: +91 22 26860011	
8	Email Address	cs@supriyalifescience.com	
9	Names of the Stock Exchanges where the Company's securities are listed	BSE Limited (BSE) National Stock Exchange of India Limited (NSE)	
		Number of Shares	% of Total Issued Capital
10	Issued Capital	80482800	
11	Listed Capital (Exchange-wise) (as per company records)	BSE 80482800 NSE 80482800	
12	Held in dematerialized form in CDSL	62561732	77.73
13	Held in dematerialized form in NSDL	17921068	22.27
14	Physical	0	0
15	Total No. of shares (12+13+14)	80482800	100.00
16	Reasons for difference if any, between (10&11), (10&15), (11&15)	N.A	
17	Certifying the Details of changes in share capital during the quarter under consideration		

C/o 211, Bldg. No.1, Sona Udyog Industrial Estate, Parsi Panchayat Road, East of Old Naqardas Road, Andheri (East), Mumbai - 400 069, (M)



Mahesh M. Darji

Practicing Company Secretary
B.Com., DBM, LLB, FCS

as per Table Below:						
Particulars ***	No. of Shares	Applied/ Not Applied For Listing	Listed on Stock Exchanges (Specify Names)	Whether Intimated to CDSL	Whether Intimated to NSDL	In-principal Approval Pending for SE (Specify Names)
NA						
*** Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify).						
18	Register of Members is updated (Yes/No) If not, updated up to which date.					Yes
19	Reference of previous quarter with regard to excess dematerialised shares, if any.					Nil
20	Has the Company resolved the matter mentioned in Point No. 19 above in the current quarter? If not, reason why?					N.A.
21	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 30 days with the reasons for delay					
Total No. of Demat Request			No. of Request	No. of Shares	Reasons for Delay	
Confirmed after 21 Days (from the date of receipt of DRF by RTA)			---	---	---	
Pending for more than 21 days (from the date of receipt of DRF by RTA)			---	---	---	
22	Name, Telephone & Fax No. of the Compliance Officer of the Company		Shweta Singh 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063 Tel. No. +91 22 40332727; Email: cs@supriyalifescience.com			
23	Name, Address, Tel. & Fax No., Registration no. of the Auditor		Mahesh Darji (C.S.) FCS - 7175 C.P. - 7809 211, Building No. 1, Sona Udyog, Parsi Panchayat Road, Andheri (E), Mumbai - 400 069. Email: mahesh@ngshah.com Tel. 022 - 2820 3581 Tel. 022 - 2820 3582			
24	Appointment of common agency for share registry work If yes (name & address)		Link Intime India Private Limited C-101, 1 st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikroli (West), Mumbai - 400 083.			
25	Any other details that the auditor may like to provide. (E.g. BIFR company, delisting from SE, company changed its name etc.)					

Place: Mumbai


Date: 12.10.2022

UDIN: F007175D001200675

(MAHESH M. DARJI)

Company Secretary

C.P. No: 7809



C/o 211, Bldg. No.1, Sona Udyog Industrial Estate, Parsi Panchayat Road, Extn.
of Old Naqardas Road, Andheri 400 069, (M) +91 9819196693